Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
The company’s matching strategy for CB-010 will soon be put to the test.
Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
Party season approaches; but first, conferences.